The most award winning
healthcare information source.
TRUSTED FOR FOUR DECADES.
SOURCE: Jakobsen GS, et al. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities. JAMA 2018;319:291-301.
For most patients, managing obesity is a long-term endeavor. Recent proliferation of oral and parenteral anti-obesity agents has increased the number of pharmacologic treatments. Still, long-term weight reduction achieved with such treatments, in combination with lifestyle interventions, is modest (typically, 5-10% body weight decline). Additionally, pharmacologic treatments are not disease-modifying; that is, after medication cessation, weight regain occurs consistently and predictably.
Obesity surgery produces prompt and highly effective metabolic changes that favorably affect prevalent and incident diabetes and hypertension. But do these results last? To answer that question, Jakobsen et al reported on a 10-year follow-up of patients with obesity who were offered their choice of surgical or intensive medical treatment (n = 1,888) at a publicly funded tertiary care obesity center in Norway.
Outcomes differences between the groups were dramatic. Subjects who chose surgical treatment were twice as likely to go into hypertension remission, four times less likely to develop new onset hypertension, and four times more likely to experience remission of diabetes than medically treated subjects. Although surgical intervention was not without adverse effects, including a difficult-to-explain modest increased incidence of depression, metabolic benefits were consistent and enduring. The evidence of the advantages of bariatric surgery over medical management continues to accrue.
Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Brunton reports he is a retained consultant for Abbott Diabetes, Becton Dickinson, Boehringer Ingelheim, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, and Novo Nordisk. Dr. Kuritzky (author) is a retained consultant for and on the speakers bureau of Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Ms. Coplin, Mr. Springston, and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.
Please update your cookie consent to make our free e-newsletters available to you by opting into marketing content.
If you are using an ad-blocker, you may also be unable to access our free content, you would need to enable scripts from marketo.com